Summary of "[다큐S프라임] 의학의 미래를 책임지는 바이오뱅크 / YTN 사이언스"

What a biobank is and why it matters

Biobanks collect, store and distribute human biological materials (blood, urine, tissues, DNA/RNA, stool, saliva, eggs, umbilical cords, etc.) together with linked clinical and lifestyle data. They are core infrastructure for precision medicine, drug discovery, rare‑disease research, epidemiology and public‑health surveillance. Large, well‑annotated biobank datasets enable personalized diagnosis, prediction and treatment.

Global examples and impacts

UK Biobank
- Recruited roughly 500,000 adults between 2006 and 2013.
- Pre‑pandemic records were linked to COVID‑19 test results to reveal long‑term, multi‑organ impacts of SARS‑CoV‑2.
- The UK uses coded cohorts to accelerate drug and diagnostic research and plans further scale‑up (target cited: ~5 million).
US “All of Us” program
- Started around 2015 with a goal of 1 million diverse participants.
- Used during the COVID‑19 pandemic for antibody analyses and studies of socioeconomic and health impacts.
- Note: some captions transcribe the name as “Olbers.”
Finland’s FIN project
- Government‑led program (from 2017) combining genomics with national health records.
- Has collected genomic data from ~500,000 people (~10% of the population).
- Legislative framework (Biobank Act and secondary‑use acts) has encouraged private‑sector R&D.
Market estimate
- Mordor Intelligence projected the global biobank market to grow from about USD 50 billion (2023) to USD 64 billion (2028).

Korea’s biobank ecosystem and initiatives

National infrastructure
- Korean Human Bioresource Bank project (KCDC/KDCA) launched in 2008.
- National Central Human Bioresource Bank and a network of hospital/private biobanks.
Scale and outputs
- National banks report ~1 million biological samples stored (including ~450,000 from population projects; KBN cited with 660,000 sets).
- Samples distributed to hundreds of research projects; supported COVID‑19 diagnostic test development (emergency use authorization and export approvals).
- Produced publications and patents.
National Integrated Bio Big Data Construction Project
- Government plan to collect genomic and clinical data from 1 million people (including ~47,000 rare disease patients) across 2024–2032.
- Pilot work has begun; a proposed “Bio Data Bank” one‑stop access system aims to reduce transaction friction for researchers.
- Emphasis on Korean‑specific genomic data because population differences (e.g., KCNQ1 diabetes risk variant common in East Asians but rare in Europeans) mean European‑derived risk models can underperform.

Specialized biobanks and applications

Cancer and tissue banks
- Hospital biobanks store blood, tissue and cell samples from cancer and rare cancer patients for biomarker discovery and technology validation (for example, comparing mutated tissue to matched normal tissue).
Environmental health sample bank (Incheon)
- Stores ~1.1 million samples from ~100,000 people.
- Runs the Children’s Environmental Health Birth Cohort (recruiting ~70,000 pregnant women from 2015) with follow‑up into adulthood (through ~2036).
- Stores maternal and cord samples to study lifelong effects of environmental exposures.
- Samples kept in liquid nitrogen (about −180 °C); periodic QC uses certified standards spiked into samples and checks concentrations every two years.
Egg/embryo banks and vitrification (fertility preservation)
- Vitrification (rapid freezing) developed circa 1998 yields high post‑thaw survival.
- First reported successful birth from eggs frozen before cancer treatment after 9 years (reported in 2012).
- Growing elective egg‑freezing use has demographic relevance for low birthrate/aging societies and potential applications in autologous egg‑derived stem cell therapies.
Microbiome and fecal banks
- Collect stool, colon tissue, saliva and related specimens for microbiome research and fecal microbiota transplantation (FMT).
- FMT is established for recurrent C. difficile infection and is being trialed for antibiotic‑resistant IBS and colitis.
- Gut–brain axis research links the microbiome to neurodegenerative and psychiatric conditions.
Oral and oral‑cavity biobanks (dental hospitals)
- Collect teeth, saliva, plaque, gingival fluid and oral tissues.
- Storage temperatures vary by tissue type (example: teeth at 4 °C; plaque/saliva at ~−80 °C; cells/tissues in liquid nitrogen at ~−196 °C).
- Supports biomarker discovery for oral cancers and research on periodontal–systemic disease links.

Technical methods and operational practices

Sample collection and consent
- Samples come from large population projects and leftover clinical specimens with donor consent.
- Consent procedures are complex; electronic consent is being introduced but public understanding remains limited.
Aliquoting and sample handling
- Large specimens are subdivided into many small aliquots at collection to avoid repeated freeze–thaw cycles and to maximize downstream usability.
- Each aliquot is assigned a unique ID (e.g., laser‑printed serials) for traceability.
Temperature and storage
- Short‑term and tissue‑specific storage temperatures are tailored to sample type: common ranges include −80 °C to −120 °C (mechanical freezers) and liquid nitrogen storage at about −196 °C (some tanks cited at −180 °C).
- Environmental banks use certified standards spiked into samples and monitor concentrations biennially to detect system drift.
Egg freezing (vitrification) workflow
1. Assess ovarian function (ultrasound, blood tests).
2. Ovulation induction injections for ~10–11 days to mature multiple oocytes.
3. Retrieval and rapid vitrification.
4. Store in liquid nitrogen until thawing and fertilization for embryo transfer.
Fecal microbiota transplantation (FMT) workflow
1. Donor screening (blood tests, infectious disease screening including COVID‑19).
2. Stool donation and laboratory processing to remove debris and pathogens.
3. Preparation into a microbial suspension and storage at about −60 °C.
4. Thaw ~6 hours before administration (via endoscopy, enema or infusion).
Genomic association analysis (Korean example)
- Whole‑genome association analysis links genomic variants to phenotypes across thousands of individuals to identify disease‑associated variants.
- Example: Professor Lee Seung‑geun analyzed genome + phenotype data from ~72,000 Koreans, performed GWAS across six phenotypes and identified 122 associated variants — illustrating the value of population‑specific analyses.

Challenges and considerations

Ethical, legal and regulatory: complex consent processes and strict personal data protection laws can limit data use; calls exist for regulatory flexibility while maintaining privacy safeguards.
Public perception and donation rates: biobank research depends on donor participation; raising awareness and trust is essential.
Technical and governance: needs include standardization across institutions, long‑term sample QA/QC, interoperability and one‑stop data access.
Industry collaboration: partnerships with industry are needed to translate biobank assets into diagnostics, therapeutics and precision‑medicine products.

Researchers and sources featured

Professor Lee Seung‑geun — Graduate School of Data Science (Korean GWAS on ~72,000 individuals)
UK Biobank
US “All of Us” program (sometimes auto‑captioned as “Olbers”)
FIN project (Finland’s national precision‑medicine/biobank program)
Mordor Intelligence (market projection)
The Times (cited biobanking as an innovative future technology in 2009)
Korea Centers for Disease Control and Prevention (KCDC) / Korea Disease Control and Prevention Agency (KDCA)
National Central Human Bioresource Bank (Korea)
Korea Bioresource Network (KBN)
Ministry of Health and Welfare (Korea)
Ministry of Science and ICT (Korea)
Ministry of Trade, Industry and Energy (Korea)
National Environmental Health Sample Bank (Incheon) and the Children’s Environmental Health Birth Cohort Project
National University Dental Hospital and Korea National Biobank Network
Hospital biobanks (including major university hospitals and anonymized hospitals in Gangnam)
Microbiome Centers / Kids School Microbiome Center and I‑University Hospital (leaders in FMT and C. difficile trials)

Note: some auto‑caption errors appeared in the original material (for example, “Olbers” likely refers to the US All of Us program, and a few institution names were partially garbled).